Business, energy, technology, markets and global industry news from Business News Today

PrecivityAD2

PharmaDeviceNews PrecivityAD2
C2N Diagnostics’ FDA-cleared PrecivityAD2 blood test combines amyloid and tau biomarker measurements using mass spectrometry to aid Alzheimer’s disease assessment in symptomatic adults aged 40 and older. Representative image.
Medical Devices & Diagnostics

C2N Diagnostics takes Alzheimer’s blood testing younger as FDA clears PrecivityAD2 from age 40

C2N Diagnostics’ FDA-cleared PrecivityAD2 combines amyloid and tau measurements in a mass-spectrometry test intended to aid assessment of symptomatic adults aged 40 and older.

Read More
Anthem coverage of C2N Diagnostics’ PrecivityAD2 blood test could expand access to Alzheimer’s disease evaluation through blood-based biomarker testing. Representative image.
Medical Devices & Diagnostics

C2N Diagnostics gains Anthem coverage for PrecivityAD2 blood-based Alzheimer’s evaluation

Anthem will cover C2N Diagnostics’ PrecivityAD2 from October 2026. Read what the move means for Alzheimer’s blood testing access.

Read More
C2N Diagnostics expands PrecivityAD2 blood test into South Korea as Alzheimer’s diagnostics market shifts toward earlier detection
Medical Devices & Diagnostics

Can blood-based Alzheimer’s diagnostics change clinical practice? C2N Diagnostics enters South Korea with PrecivityAD2

C2N Diagnostics brings its PrecivityAD2 blood test to South Korea through BeauBrain Healthcare. Discover what this means for Alzheimer’s diagnosis.

Read More